[The guideline of prevention and treatment for chronic hepatitis B: a 2015 update].
about
Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection.Ceruloplasmin, a reliable marker of fibrosis in chronic hepatitis B virus patients with normal or minimally raised alanine aminotransferase.Real-time PCR assays for hepatitis B virus DNA quantification may require two different targets.Cell death biomarker M65 is a useful indicator of liver inflammation and fibrosis in chronic hepatitis B: A cross-sectional study of diagnostic accuracyHepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2aEntecavir for Patients with Hepatitis B Decompensated Cirrhosis in China: a meta-analysis.Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China.Different Mechanisms May Exist for HBsAg Synthesis and Secretion During Various Phases of Chronic Hepatitis B Virus Infection.The effects of the insulin resistance index on the virologic response to entecavir in patients with HBeAg-positive chronic hepatitis B and nonalcoholic fatty liver disease.Dynamic Perturbations of CD4 and CD8 T Cell Receptor Repertoires in Chronic Hepatitis B Patients upon Oral Antiviral Therapy.Identification and characterization of interferon signaling-related microRNAs in occult hepatitis B virus infection.Sevoflurane may be more beneficial than propofol in patients receiving endoscopic variceal ligation and endoscopic variceal sclerotherapy: A randomized, double-blind study.Negative Correlation of Serum Hepatitis B Surface Antigen and Hepatitis B e Antigen Levels with the Severity of Liver Inflammation in Treatment-naïve Patients with Chronic Hepatitis B Virus Infection.Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels.Hepatitis B virus infection in an HBsAb-positive lymphoma patient who received chemotherapy: A case report.Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010-2016).Value of the albumin-bilirubin score in the evaluation of hepatitis B virus-related acute-on-chronic liver failure, liver cirrhosis, and hepatocellular carcinoma.Clinical Characteristics and Correlation Analysis of Subjects with Chronic Hepatitis B Virus (HBV) Infection and Sustained Low Levels of Hepatitis B Surface Antigen (HBsAg).Upgrade Combination Response Is Limited by Prolonged Nucelos(t)ide Analogue Therapy in HBeAg-positive Chronic Hepatitis B: A Real-life Study.Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B.Animal models for the study of hepatitis B virus infection.Estimating the impact of test-and-treat strategies on hepatitis B virus infection in China by using an age-structured mathematical model.Immunogenicity and safety of high-dose hepatitis B vaccine among drug users: A randomized, open-labeled, blank-controlled trial.JianPi HuaZhuo XingNao formula (Chinese herbal medicine) for the treatment of minimal hepatic encephalopathy: a protocol for a randomized, placebo-controlled pilot trial.Chinese woodchucks with different susceptibility to WHV infection differ in their genetic background exemplified by cytochrome B and MHC-DRB molecules.Prevalence of hepatitis B virus, hepatitis C virus, human immunodeficiency virus and Treponema pallidum infections in hospitalized patients before transfusion in Xiangya hospital Central South University, China from 2011 to 2016.Presence of hepatitis B virus in synovium and its clinical significance in rheumatoid arthritis.Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment.Sequence analysis of the Pre-S gene in chronic asymptomatic HBV carriers with low-level HBsAg
P2860
Q26740195-68897DCF-F765-4D5C-A16E-B652922E22CBQ30368428-A9970996-70A7-440B-9C7A-3B058E61AB87Q33667860-930410E7-1B9E-44AB-9FA0-F3D944BFD2F5Q33714356-2E2BC337-E742-4A9C-9AC4-C8CFB160C61DQ36924978-996CBC89-E3E6-4E1C-9CE2-62FA0BE81F6CQ37236357-37B79E0D-8F57-4BA5-B0B1-806FC2C52DB1Q37501060-E4F5A04E-9782-4FCF-B25B-1A18800EDBA0Q37719675-B0E2494B-1229-4637-9364-68CC7E2388C2Q37726148-15563F63-C607-4E5F-AF49-6FF683C0078BQ40584415-06033FC1-776A-4072-AFF6-9E387E33920FQ41673040-99790ED8-013A-4757-9274-611388721903Q41712670-CCDB792F-63D7-4395-A85F-A340668061B2Q42364648-A3C20F93-62CA-4C5D-80CF-BE1BF562B069Q45324890-C29F7188-B18C-46D3-AEBE-BB518C977FA9Q45325386-C08511C1-88FB-4770-AFBE-25BE30426207Q45325391-3F2A98AC-7AC8-490B-BFAF-275EAB00B62EQ47585685-CDDD5427-4AF7-46AE-8FE8-20D254300D66Q49875117-1C1ADA4B-725D-4BE9-A2FD-0E07E41E5A6AQ52624925-05AD9F0C-0925-4419-AF3F-73CA5A3EA396Q52632458-AEE03274-2611-4A4F-8218-EDD98D8962D9Q52632461-0765EF14-B520-47A7-847F-4F23ADCB90D4Q52671153-4CDFEBF8-7BDA-427B-8263-604A18F1D2FEQ54233290-9E7C7954-FD13-4813-82D9-BCC6CA8E928AQ54408166-6077F7F6-8CE4-409B-B01E-94C4B111DB94Q55113828-76963F69-F5F6-4A88-99C7-30BE025B485BQ55304574-66ACE6A6-7F68-44D3-965C-62DBA607526EQ55344900-E23DBA90-C305-47E8-A454-7F9766B34D4AQ55379977-3B069EE5-FD85-4AAB-90B0-D73421E08F50Q55517833-DC751CE5-16AC-4C7C-B4CD-46D984B5FEBFQ58767321-73AC2845-6E1F-46B5-8329-FD7E0148B593
P2860
[The guideline of prevention and treatment for chronic hepatitis B: a 2015 update].
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
[The guideline of prevention and treatment for chronic hepatitis B: a 2015 update].
@en
type
label
[The guideline of prevention and treatment for chronic hepatitis B: a 2015 update].
@en
prefLabel
[The guideline of prevention and treatment for chronic hepatitis B: a 2015 update].
@en
P2093
P1476
[The guideline of prevention and treatment for chronic hepatitis B: a 2015 update].
@en
P2093
Chinese Society of Hepatology, Chinese Medical Association
Chinese Society of Infectious Diseases, Chinese Medical Association
Jin-Lin Hou
P304
P356
10.3760/CMA.J.ISSN.1007-3418.2015.12.002
P407
P577
2015-12-01T00:00:00Z